Patrick Worrall

AstraZeneca has committed to delivering 2 million doses of vaccine a week, but it’s not easy to check whether this benchmark is being hit.

AstraZeneca said the numbers of people reporting serious blood clotting disorders after receiving its Covid vaccine were “much lower than would be expected to occur naturally in a general population of this size”.

Most NHS workers have faced significant pay cuts over the last ten years, when you adjust for inflation.

It’s a massive change in policy – the first time a UK chancellor has raised the headline rate of corporation tax in decades.

Hospitalisation and death rates have been falling faster among the oldest. This didn’t happen after the first wave of the pandemic.

New figures released by the government suggest the flow of goods being exported from Britain to Europe may have fallen in January, but it appears to have bounced back.

“Keir accepts that, on this occasion, the Prime Minister was referring to old comments about the European Medicines Agency and Keir admits he was wrong and made a mistake in his response.”

Ministers have insisted the UK is on track to hit a target of offering a Covid-19 vaccine to almost 14 million people by the middle of next month. But questions remain about the supply of vaccines.

The World Health Organization has said it does not recommend the approach Britain is taking in vaccinating large numbers of people against coronavirus. Should we be worried? 

All the evidence suggests the number of vaccine doses available for immediate use falls well short of the 40 million that we were originally supposed to have by this stage.

A senior official from Kent County Council’s Highways department said there were “nearer 500” lorries involved in Operation Stack.

Here’s what we know and what we don’t know, according to some of the country’s leading experts.

The first batch of Pfizer vaccine to arrive in the UK consists of just 800,000 doses, but NHS bosses say they expect to have more by the end of the year.

The coronavirus vaccine developed by Oxford University is under scrutiny after the makers admitted an error had led to different groups getting different doses in clinical trials.